<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2024-3078</article-id><article-id custom-type="edn" pub-id-type="custom">UDNFZC</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3078</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>The oxytocin-oxytocin receptors system — a new pathogenetic mechanism in the development of diabetic phenotype of heart failure with preserved ejection fraction in women</article-title><trans-title-group xml:lang="ru"><trans-title>Система окситоцин-окситоциновые рецепторы — новый патогенетический механизм в развитии диабетического фенотипа сердечной недостаточности с сохраненной фракцией выброса у женщин</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7892-1841</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Старченко</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Starchenko</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Старченко Анастасия Дмитриевна - ассистент кафедры внутренних болезней.</p><p>Оренбург</p></bio><bio xml:lang="en"><p>Anastasiya D. Starchenko.</p><p>Orenburg</p></bio><email xlink:type="simple">doctornastenka@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6271-8841</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лискова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Liskova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лискова Юлия Владимировна - д.м.н., профессор кафедры факультетской терапии лечебного факультета.</p><p>Москва</p></bio><bio xml:lang="en"><p>Yulia V. Liskova.</p><p>Moscow</p></bio><email xlink:type="simple">liskovaj@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6107-0534</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стадников</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stadnikov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Стадников Александр Абрамович - з.д.н. РФ, д.б.н., профессор, зав. кафедрой гистологии, цитологии и эмбриологии.</p><p>Оренбург</p></bio><bio xml:lang="en"><p>Alexander A. Stadnikov.</p><p>Orenburg</p></bio><email xlink:type="simple">alexander.stadnikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Оренбургский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Orenburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2024</year></pub-date><volume>20</volume><issue>4</issue><fpage>378</fpage><lpage>385</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Starchenko A.D., Liskova Y.V., Stadnikov A.A., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Старченко А.Д., Лискова Ю.В., Стадников А.А.</copyright-holder><copyright-holder xml:lang="en">Starchenko A.D., Liskova Y.V., Stadnikov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3078">https://www.rpcardio.online/jour/article/view/3078</self-uri><abstract><sec><title>Aim</title><p>Aim. To determine the pathogenetic role of the oxytocinergic system in the development of myocardium structural and functional changes in women with heart failure with preserved ejection fraction (HFpEF) associated with type 2 diabetes mellitus (DM2T) (diabetic phenotype of HFpEF).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 60 women aged 67.0±4.9 years with HFpEF stage I-IIA, FC I-III, 30 of them had DM2T who were admitted for elective coronary artery bypass grafting. The development of HFpEF is caused by coronary artery disease (CAD) and arterial hypertension (AH). Prior to surgery, all patients underwent a standard examination, blood levels of NT-proBNP, oxytocin (Ox), echocardiography were determined to find the types of left ventricular (LV) myocardial remodeling and diastolic dysfunction (DD). Myocardium biopsies of the right atrium auricle obtained during coronary bypass surgery were studied by microscopy, morphometry and immunohistochemistry (the expression of oxytocin receptors (OxR), a marker of proliferation ki-67).</p></sec><sec><title>Results</title><p>Results. According to echocardiography, eccentric LV hypertrophy (46.7/36.7%) and DD type 2 (47/17%, p=0.003) prevailed in the group of women with the diabetic phenotype of HFpEF. A higher content of NT-proBNP (480.72±241.87/434.46±282.78 ng/ml, p=0.06) and a lower concentration of Ox (102.11±35.89/320.37±294.71 pg/ml, p=0.0016) in blood serum were established, as well as an increase in the number of cardiomyocytes (CMC) with a high expression level OxR (63.69±19.47/12.16±23.09%, p=0.000) in patients with the diabetic phenotype of HFpEF. Negative associations were determined between the blood level of Ox and the CMC diameter (r=-0.10, p=0.020), the area of their cytoplasm (r=-0.16, p=0.000) and the area of the nuclei (r=-0.11, p=0.015) in patients of both groups. A decrease in Ox concentration in the blood of patients with diabetic phenotype of HFpEF was accompanied by an increase in the number of CMCs with a high level of OxR expression (r=-0.63, p=0.000).</p></sec><sec><title>Conclusion</title><p>Conclusion. The study has shown the important involvement of oxytocinergic signaling pathways in the HFpEF pathogenesis. HFpEF associated with DM2T in women was characterized by more unfavorable structural and functional changes in the myocardium, a significant increase in the number of hypertrophied CMCs with a high level of OxR expression and Ox decrease in blood serum. The mechanisms of the first-established significant increase in the content of Ox in the blood of patients with HFpEF without diabetes and its significant decrease in patients with diabetic phenotype of HFpEF leading to more pronounced structural and functional changes in the myocardium, require further study.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Определить патогенетическую роль окситоцинергической системы в развитии структурно-функциональных изменений миокарда у женщин с сердечной недостаточностью с сохраненной фракцией выброса (СНсФВ), ассоциированной с сахарным диабетом 2 типа (СД2Т) (диабетический фенотип (ДФ) СНсФВ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены 60 женщин в возрасте 67,0±4,9 лет с СНсФВ I-IIА стадии, I-III функционального класса (ФК), из них 30 на фоне СД2Т, поступившие для планового аортокоронарного шунтирования (АКШ). СНсФВ развилась вследствие ишемической болезни сердца (ИБС) и артериальной гипертонии (АГ). До АКШ всем пациентам выполнено стандартное обследование, определены уровни N-концевого фрагмента натрийуретического пропептида В-типа (NT-proBNP), окситоцина (Ох) крови, проведено эхокардиографическое исследование (ЭхоКГ) с определением типов ремоделирования миокарда левого желудочка (ЛЖ) и диастолической дисфункции (ДД). Биоптаты миокарда ушка правого предсердия, полученные при проведении АКШ на этапе канюляции полых вен, изучены методами световой микроскопии, морфометрии и иммуногистохимии (с оценкой экспрессии окситоциновых рецепторов (OxR), маркера пролиферации ki-67).</p></sec><sec><title>Результаты</title><p>Результаты. По данным ЭхоКГ эксцентрическая гипертрофии ЛЖ (46,7/36,7% — с/без СД2Т, соответственно) и ДД 2 типа (47/17% — с/без СД2Т, р=0,003) чаще встречались в группе женщин с ДФ СНсФВ по сравнению с пациентками без диабета. Установлена более высокая концентрация NT-proBNP (480,72±241,87/434,46±282,78 нг/мл, р=0,06) и низкая Ох (102,11±35,89/320,37±294,71 пг/мл, р=0,002) в сыворотке крови, а также увеличение числа кардиомиоцитов (КМЦ) с высоким уровнем экспрессии ОхR в миокарде (63,69±19,47/12,16±23,09%, р&lt;0,001) у пациентов с ДФ СНсФВ. Определены отрицательные связи между уровнем Ох крови и диаметром КМЦ (r=-0,10, p=0,020), площадью их цитоплазмы (r=-0,16, p&lt;0,001) и площадью ядер (r=-0,11, p=0,015) независимо от наличия СД2Т. Снижение концентрации Ох в крови у пациенток с ДФ СНсФВ сопровождалось ростом числа КМЦ с высоким уровнем экспрессии OxR (r=-0,63, p&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Показана существенную роль окситоцинергических сигнальных путей в патогенезе СНсФВ у женщин. ДФ СНсФВ характеризовался более неблагоприятными структурно-функциональными изменениями миокарда, статистически значимым увеличением числа гипертрофированных КМЦ с высоким уровнем экспрессии ОхR и снижением Ох в сыворотке крови. Механизмы значимого увеличения содержания Ох в крови у пациентов с СНсФВ без СД2Т и его снижение у пациентов с ДФ СНсФВ, впервые установленные в нашей работе, требуют дальнейшего изучения.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>ремоделирование миокарда</kwd><kwd>патогенез</kwd><kwd>окситоцин</kwd><kwd>окситоциновые рецепторы</kwd><kwd>женский пол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>cardiac remodeling</kwd><kwd>pathogenesis</kwd><kwd>oxytocin</kwd><kwd>oxytocin receptors</kwd><kwd>female</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при поддержке Оренбургского государственного медицинского университета.</funding-statement><funding-statement xml:lang="en">The study was carried out with the support of Orenburg State Medical University.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Conlon FL, Arnold AP. Sex chromosome mechanisms in cardiac development and disease. Nat Cardiovasc Res. 2023;2(4):340-50. DOI:10.1038/s44161-023-00256-4.</mixed-citation><mixed-citation xml:lang="en">Conlon FL, Arnold AP. Sex chromosome mechanisms in cardiac development and disease. Nat Cardiovasc Res. 2023;2(4):340-50. DOI:10.1038/s44161-023-00256-4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Barton M, Meyer MR. Heart failure with preserved ejection fraction in women: new clues to causes and treatment. JACC Basic Transl Sci. 2020;5(3):296-9. DOI:10.1016/j.jacbts.2020.02.001.</mixed-citation><mixed-citation xml:lang="en">Barton M, Meyer MR. Heart failure with preserved ejection fraction in women: new clues to causes and treatment. JACC Basic Transl Sci. 2020;5(3):296-9. DOI:10.1016/j.jacbts.2020.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sabbatini AR, Kararigas G. Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week. J Am Coll Cardiol. 2020;75(9):1074-82. DOI:10.1016/j.jacc.2019.12.049.</mixed-citation><mixed-citation xml:lang="en">Sabbatini AR, Kararigas G. Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week. J Am Coll Cardiol. 2020;75(9):1074-82. DOI:10.1016/j.jacc.2019.12.049.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer S, van der Meer P, van Deursen VM, et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34(32):2538-47. DOI:10.1093/eurheartj/eht152.</mixed-citation><mixed-citation xml:lang="en">Meyer S, van der Meer P, van Deursen VM, et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34(32):2538-47. DOI:10.1093/eurheartj/eht152.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015;36(40):2677-80. DOI:10.1093/eurheartj/ehv161.</mixed-citation><mixed-citation xml:lang="en">Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015;36(40):2677-80. DOI:10.1093/eurheartj/ehv161.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015;9:37. DOI:10.3389/fnins.2015.00037.</mixed-citation><mixed-citation xml:lang="en">Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015;9:37. DOI:10.3389/fnins.2015.00037.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kawai A, Nagatomo Y, Yukino-Iwashita M, et al. Sex Differences in Cardiac and Clinical Phenotypes and Their Relation to Outcomes in Patients with Heart Failure. J Pers Med. 2024;14(2):201. DOI:10.3390/jpm14020201.</mixed-citation><mixed-citation xml:lang="en">Kawai A, Nagatomo Y, Yukino-Iwashita M, et al. Sex Differences in Cardiac and Clinical Phenotypes and Their Relation to Outcomes in Patients with Heart Failure. J Pers Med. 2024;14(2):201. DOI:10.3390/jpm14020201.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay SM, Givertz MM, Aguilar D, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Heart Failure Society of America. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):294-324. DOI:10.1161/CIR.0000000000000691.</mixed-citation><mixed-citation xml:lang="en">Dunlay SM, Givertz MM, Aguilar D, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Heart Failure Society of America. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):294-324. DOI:10.1161/CIR.0000000000000691.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyper­glycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21-28. DOI:10.1007/s00125-017-4390-4.</mixed-citation><mixed-citation xml:lang="en">Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyper­glycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21-28. DOI:10.1007/s00125-017-4390-4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ding C, Leow MK, Magkos F. Oxytocin in metabolic homeostasis: implica­­tions for obesity and diabetes management. Obes Rev. 2019;20(1):22-40. DOI:10.1111/obr.12757.</mixed-citation><mixed-citation xml:lang="en">Ding C, Leow MK, Magkos F. Oxytocin in metabolic homeostasis: implica­­tions for obesity and diabetes management. Obes Rev. 2019;20(1):22-40. DOI:10.1111/obr.12757.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jankowski M, Broderick TL, Gutkowska J. The role of oxytocin in cardiovascu­lar protection. Front Psychol. 2020;11:516048. DOI:10.3389/fpsyg.2020.02139.</mixed-citation><mixed-citation xml:lang="en">Jankowski M, Broderick TL, Gutkowska J. The role of oxytocin in cardiovascu­lar protection. Front Psychol. 2020;11:516048. DOI:10.3389/fpsyg.2020.02139.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation><mixed-citation xml:lang="en">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. DOI:10.1016/j.echo.2014.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Терещенко С. Н., Галявич А. С., Ускач Т. М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;11:311-74. DOI:10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">Tereshchenko SN, Galyavich AS, Uskach TM, et al. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;11:311-74 (In Russ.) DOI:10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Автандилов Г. Г. Медицинская морфометрия. М.: Медицина, 1990.</mixed-citation><mixed-citation xml:lang="en">Avtandilov GG. Medical morphometry. M.: Medicina, 1990 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И. И., Шестакова М. В., Майоров А. Ю. и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. DOI:10.14341/DM12507.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakov MV, Majorov AI, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102 (In Russ.) DOI:10.14341/DM12507.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550-60. DOI:10.1007/s00125-019-4926-x.</mixed-citation><mixed-citation xml:lang="en">Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550-60. DOI:10.1007/s00125-019-4926-x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Benomar K, Espiard S, Loyer C, et al. Hormones natriurétiques et syndrome métabolique: mise au point. Presse Med. 2018;47(2):116-24 (In French) [Benomar K, Espiard S, Loyer C, et al. Atrial natriuretic hormones and metabo­­lic syndrome: recent advances. Presse Med. 2018;47(2):116-24]. DOI:10.1016/j.lpm.2017.12.002.</mixed-citation><mixed-citation xml:lang="en">Benomar K, Espiard S, Loyer C, et al. Hormones natriurétiques et syndrome métabolique: mise au point. Presse Med. 2018;47(2):116-24 (In French) [Benomar K, Espiard S, Loyer C, et al. Atrial natriuretic hormones and metabo­­lic syndrome: recent advances. Presse Med. 2018;47(2):116-24]. DOI:10.1016/j.lpm.2017.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jankowski M, Broderick TL, Gutkowska J. Oxytocin and cardioprotection in diabetes and obesity. BMC Endocr Disord. 2016;16(1):34. DOI:10.1186/s12902-016-0110-1.</mixed-citation><mixed-citation xml:lang="en">Jankowski M, Broderick TL, Gutkowska J. Oxytocin and cardioprotection in diabetes and obesity. BMC Endocr Disord. 2016;16(1):34. DOI:10.1186/s12902-016-0110-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021;128(10):1451-67. DOI:10.1161/circresaha.121.318159.</mixed-citation><mixed-citation xml:lang="en">Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021;128(10):1451-67. DOI:10.1161/circresaha.121.318159.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kajstura J, Gurusamy N, Ogórek B, et al. Myocyte turnover in the aging human heart. Circ Res. 2010;107(11):1374-86. DOI:10.1161/CIRCRESAHA.110.231498.</mixed-citation><mixed-citation xml:lang="en">Kajstura J, Gurusamy N, Ogórek B, et al. Myocyte turnover in the aging human heart. Circ Res. 2010;107(11):1374-86. DOI:10.1161/CIRCRESAHA.110.231498.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay SM, Roger VL. Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep. 2012;9(4):267-76. DOI:10.1007/s11897-012-0107-7.</mixed-citation><mixed-citation xml:lang="en">Dunlay SM, Roger VL. Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep. 2012;9(4):267-76. DOI:10.1007/s11897-012-0107-7.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Biondi-Zoccai G, Abate A, Bussani R, et al. Reduced post-infarction myocar­dial apoptosis in women: a clue to their different clinical course? Heart. 2005;91(1):99-101. DOI:10.1136/hrt.2003.018754.</mixed-citation><mixed-citation xml:lang="en">Biondi-Zoccai G, Abate A, Bussani R, et al. Reduced post-infarction myocar­dial apoptosis in women: a clue to their different clinical course? Heart. 2005;91(1):99-101. DOI:10.1136/hrt.2003.018754.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Старченко А. Д., Лискова Ю. В., Стадников А. А., Мясникова А. А. Оценка влияния окситоцина на структурно-функциональные изменения миокарда при экспериментальной сердечной недостаточности. Журнал анатомии и гистопатологии. 2024;13(2):54-62. DOI:10.18499/2225-7357-2024-13-2-54-62.</mixed-citation><mixed-citation xml:lang="en">Starchenko AD, Liskova YuV, Stadnikov AA, Myasnikova AA. Evaluation of the effect of oxytocin on structural and functional changes of the myocardium in experimental heart failure. Journal of Anatomy and Histopathology. 2024;13(2):54-62 (In Russ.) DOI:10.18499/2225-7357-2024-13-2-54-62.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myo­cytes divide after myocardial infarction. N Engl J Med. 2011;344(23):1750-7. DOI:10.1056/NEJM200106073442303.</mixed-citation><mixed-citation xml:lang="en">Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myo­cytes divide after myocardial infarction. N Engl J Med. 2011;344(23):1750-7. DOI:10.1056/NEJM200106073442303.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112(15):2254-62. DOI:10.1161/CIRCULATIONAHA.105.541078.</mixed-citation><mixed-citation xml:lang="en">Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112(15):2254-62. DOI:10.1161/CIRCULATIONAHA.105.541078.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kraus D, Jäger J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37(7):455-9. DOI:10.1055/s-2005-870240.</mixed-citation><mixed-citation xml:lang="en">Kraus D, Jäger J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37(7):455-9. DOI:10.1055/s-2005-870240.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
